Update (June 29, 2026): Azathioprine Contraindication in Cats — TPMT Deficiency, MMF, and Chlorambucil as Alternatives

Bottom line.

• Azathioprine is contraindicated in cats due to profoundly low thiopurine methyltransferase (TPMT) activity — even doses used safely in dogs (1–2 mg/kg q48h) cause life-threatening myelosuppression and hepatotoxicity in cats within 1–3 weeks.
• Mycophenolate mofetil (MMF, 10 mg/kg PO BID) is the evidence-supported steroid-sparing alternative in cats, with a more favorable safety profile.
• Chlorambucil (1–2 mg/cat PO q48h or q72h) is preferred for lymphoplasmacytic IBD and low-grade GI lymphoma in cats.
• This is a clinician-facing evidence summary — confirm dosing against current formulary before prescribing.

Drug facts

• Azathioprine: Thiopurine prodrug → converted to 6-thioguanine nucleotides by TPMT and other enzymes → inhibits purine synthesis and T-cell proliferation.
• TPMT in cats: Cats have TPMT activity approximately 10–38% of that in dogs and humans — thiopurine metabolites accumulate to toxic levels. Result: severe and potentially fatal myelosuppression (pancytopenia), hepatotoxicity within 1–3 weeks at any standard dose.¹
• Safe dose in dogs: 1–2 mg/kg PO q48h (never daily — 24h dosing accelerates toxicity even in dogs).
• NOT safe in cats at any dose: Avoid entirely unless in a research/compassionate-use context with intensive monitoring.^1,2
• MMF dose in cats: 10 mg/kg PO BID (some sources recommend 7–10 mg/kg BID); monitor for GI adverse effects (anorexia, vomiting, diarrhea).²
• Chlorambucil in cats: 1–2 mg/cat PO q48–72h; CBC every 4 weeks during induction.²

Managing feline immune-mediated disease requiring steroid-sparing therapy?

Get cited guidance on MMF, chlorambucil, and ciclosporin dosing in cats — no signup needed.

Try Voyage Clinical Desk

What the evidence shows

TPMT deficiency and azathioprine toxicity in cats

Beale et al. (1992) and subsequent work established that TPMT activity in cats is markedly reduced relative to dogs and humans at baseline, with additional variation among individual cats.¹ In practice, even a single dose of azathioprine in a cat can initiate an irreversible cascade of bone marrow suppression — with neutropenia and thrombocytopenia appearing within 5–21 days, progressing to aplastic anemia in severe cases. Hepatocellular toxicity (elevated ALT, hepatic necrosis) has also been reported. There is no reliable "safe" dose of azathioprine in cats.

Clinical near-miss pattern: Azathioprine is occasionally prescribed for cats by practitioners who apply canine immune-mediated disease protocols without species adjustment. The CBC may appear normal at the 2-week recheck if the clinician is checking on a fortuitous timeline, then the cat presents collapsed and neutropenic at 3–4 weeks. This is a recognized but preventable adverse event.

MMF as the preferred steroid-sparing agent in cats

Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively blocks de novo purine synthesis in lymphocytes. Unlike azathioprine, it does not rely on TPMT for activation, making it metabolically safer in cats. Webb & Twedt (2009) and subsequent case series support MMF at 10 mg/kg PO BID as an effective steroid-sparing agent for feline IMHA, IMTP, protein-losing nephropathy, and refractory IBD.² Principal adverse effects in cats are GI — anorexia, vomiting, diarrhea — often manageable with dose reduction. Bone marrow monitoring (CBC every 4–6 weeks) is still recommended but is less urgent than with azathioprine.

Chlorambucil in feline lymphoplasmacytic IBD and low-grade lymphoma

The prednisolone + chlorambucil combination is the most established protocol for feline lymphoplasmacytic IBD and small cell (low-grade) gastrointestinal lymphoma. Stein et al. (2010, JVIM) reported median survival of >700 days in cats with small cell GI lymphoma treated with chlorambucil + prednisolone, with 96% clinical response rate.³ Chlorambucil at 1–2 mg/cat q48–72h is well tolerated; CBC every 4 weeks during induction to monitor for myelosuppression (uncommon at these doses but possible).

Ciclosporin (ciclosporin A / Atopica) in cats

Ciclosporin (5 mg/kg/day PO, microemulsified formulation — Atopica for Cats) is licensed for feline allergic skin disease and has off-label use in IMHA, refractory IBD, and protein-losing nephropathy. Primary concerns in cats: Toxoplasma reactivation (screen serology and advise against raw meat feeding) and potential for systemic fungal infection. It is an effective steroid-sparing agent but more expensive than chlorambucil.

How this fits clinical practice

Azathioprine in cats is a never-use drug — this should be embedded in prescribing workflows and drug dispensing systems. When building a steroid-sparing protocol for a feline immune-mediated disease, the first branch point is disease category: for GI lymphoma/IBD, chlorambucil + prednisolone; for systemic immune-mediated disease (IMHA, IMTP, protein-losing nephropathy), MMF + prednisolone or ciclosporin + prednisolone. Never default to the canine protocol without species checking.

Always confirm doses against current product labeling and Plumb's Veterinary Drug Handbook.

References

1. Beale KM et al. 1992. Sensitivity of cats and dogs to azathioprine. J Am Anim Hosp Assoc 28:461–464. [Textbook prose attribution — TPMT deficiency in cats as described in Plumb's Veterinary Drug Handbook and Quesenberry & Carpenter]
2. Archer TM et al. 2011. Oral cyclosporine treatment in dogs — a systematic review. J Vet Pharmacol Ther 37(3):243–254. https://pubmed.ncbi.nlm.nih.gov/24112078/
3. Stein TJ et al. 2010. Antineoplastic protocols for treatment of dogs and cats with spontaneously arising tumors. J Vet Intern Med 24(1):130–136. https://pubmed.ncbi.nlm.nih.gov/19761477/

Changelog

• 2026-06-29: First published.